,

Use of cannabinol in the treatment of epilepsy: Lennox-Gastaut Syndrome , Dravet, and Tuberous Sclerosis Complex

Authors

Antonio Silvinato, Idevaldo Floriano, Wanderley Marques Bernardo

Published

January 30, 2023

Abstract

Purpose: The objective of this systematic review with meta-analysis was to evaluate the efficiency, safety and short and long term tolerability of Cannabidiol CBD, as an adjunct treatment , in children and adults with Dravet Syndrome (SD) and Lennox Gastaut Syndrome(LGS) or Tuberous Sclerosis Complex with inadequate control of seizures.

 
 

Full Paper>>

Citations

Silvinato, A., Floriano, I., & Bernardo, W. M. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet and Tuberous Sclerosis Complex.

/by
You might also like
Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial
Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats.
Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center
The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy